Characterization of a murine monoclonal antibody that mimics heparin- induced thrombocytopenia antibodies

Blood

Volumn 95, Issue 5, 2000, Pages 1533-1540

  Arepally, G M ^a   Kamei, S ^b   Park, K S ^b   Kamei, K ^b   Li, Z Q ^b   Liu, W ^b   Siegel, D L ^b   Kisiel, W ^b   Cines, D B ^b   Poncz, M ^b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; PROTEOHEPARAN SULFATE; THROMBOCYTE ANTIBODY; THROMBOCYTE FACTOR 4;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; MYELOMA CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 17644438477     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.5.1533.005k01_1533_1540     Document Type: Article

References (45)

1. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci 1993;305:208.
2. 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1995;104:648.
3. Amiral J, Peynaud-Debayle E, Wolf M, Bridey F, Vissac AM, Meyer D. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol. 1996;52:90.
4. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med. 1996;128:376.
5. Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol. 1998;101:653.
6. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 1997;95:1242.
7. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502.
8. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27.
9. Boshkov LK, Warkentin TE, Hayward CP, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol. 1993;84:322.
10. Lee DH, Warkentin TE, Denomme GA, Lagrotteria DD, Kelton JG, Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia. Thromb Haernost. 1998;79:50
11. Sun JS, Matik MI, Aster RH, Visentin GP. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol. 1997;54:196.
12. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/ thrombosis recognize different epitopes on heparin: platelet factor 4. Blood. 1998;91:916.
13. Amiral J, Wolf M, Fischer A, Boyer-Neumann C, Vissac A, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol. 1996;92:954.
14. 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood. 1997;89:370.
15. 131 polymorphism. Blood. 1998;92:1526.
16. 131 polymorphism in heparin-induced thrombocytopenia diagnosis. Thromb Haemost. 1998;79:523.
17. Herbert JM, Savi P, Jeske WP, Walenga JM. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost. 1998;80:326.
18. Ziporen L, Li ZQ, Park KS, et al. Defining an antigenic epitope on platelet factor 4 (PF4) associated with heparin-induced thrombocytopenia and thrombosis (HITT). Blood 1998;92:3250.
19. Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood. 1996;88:410.
20. Horsewood P, Warkentin TE, Hayward CP, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996,95:161.
21. Stern D, Nawroth P, Marcum J, et al. Interaction of antithrombin III with bovine aortic segments: role of heparin in binding and enhanced anticoagulant activity. J Clin Invest. 1985;75:272.
22. Dudek AZ, Pennell CA, Decker TD, Young TA, Key NS, Slungaard A. Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C: a potential mechanism for enhancing generation of activated protein C. J Biol Chem. 1997;272:31,785.
23. Lane RD, Crissman RS, Ginn S. High efficiency fusion procedure for producing monoclonal antibodies against weak immunogens. Methods Enzymol. 1986;121:183.
24. Park KS, Rifat S, Eck H, Adachi K, Surrey S, Poncz M. Biologic and biochemic properties of recombinant platelet factor 4 demonstrate identity with the native protein. Blood. 1990;75:1290.
25. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 1989;84:1045.
26. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologie criteria. J Clin Invest. 1973;52:2745.
27. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988;72:925.
28. Siegel DL, Silberstein LE. Expression and characterization of recombinant anti-Rh(D) antibodies on filamentous phage: a model system for isolating human red blood cell antibodies by repertoire cloning. Blood. 1994;83:2334.
29. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of Proteins of Immunological Interest. 5th ed. Bethesda, MD: National Institutes of Health; 1991.
30. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83:3232.
31. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost. 1992;67:545.
32. Greinacher A, Alban S, Dummel V, Franz G, Muellereckhardt C. Characterization of the structural requirements for a carbohydrate-based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost. 1995;74:886.
33. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71:247.
34. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93:81.
35. Hewlett MD, Hogarth PM. Molecular basis of Fc receptor function. Adv Immunol. 1994;57:1.
36. De Reys S, Blom C, Lepoudre B, et al. Human platelet aggregation by murine monoclonal anti-platelet antibodies is subtype-dependent. Blood. 1993;81:1792.
37. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95.
38. Tannenbaum SH, Finko R, Cines DB. Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol. 1986;137:1532.
39. Mayo KH, Ilyina E, Roongta V, et al. Heparin binding to platelet factor-4: an NMR and site-directed mutagenesis study: arginine residues are crucial for binding. Biochem J. 1995;312:357.
40. Fratantoni JC, Pollet R, Gralnick HR. Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods. Blood. 1975;45:395.
41. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med. 1996;128:376.
42. Rosenfeld SI, Ryan DH, Looney RJ, Anderson CL, Abraham GN, Leddy JP. Human Fc gamma receptors: stable inter-donor variation in quantitative expression on platelets correlates with functional responses. J Immunol. 1987;138:2869.
43. McCrae KR, Shattil SJ, Cines DB. Platelet activation induces increased Fc gamma receptor expression. J Immunol. 1990;144:3920.
44. Chong BH, Pilgrim RL, Cooley MA, Chesterman CN. Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood. 1993;81:988.
45. Blank M, Cines DB, Arepally G, Eldor A, Afek A, Shoenfeld Y. Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin. Clin Exp Immunol. 1997;108:333.